Foresight Diagnostics' PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas
Retrieved on:
월요일, 12월 13, 2021
Mark (given name), Nature Biotechnology, LinkedIn, Clinical trial, Physician, Center, National, Nodular lymphocyte predominant Hodgkin lymphoma, B-cell lymphoma, Phaser (effect), Neoplasm, NCI, Patient, DNA, National Institutes of Health, DLBCL, Liquid biopsy, BTK, Observation, Mutation, GLOBE, ASH, Twitter, Foresight, Classification, MRD, 3rd Plenary Session of the 11th Central Committee of the Chinese Communist Party, National Cancer Institute, CLIA, Lymphoma, Technology, AURORA, Society, Lymphoid leukemia, CT scan, Medical imaging, Acalabrutinib
The study ( abstract #524 ) was described in a podium presentation at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.
Key Points:
- The study ( abstract #524 ) was described in a podium presentation at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.
- The open label trial is evaluating patients with newly diagnosed aggressive B-cell lymphoma and is designed such that patients first received the BTK inhibitor acalabrutinib for up to 14 days.
- Patients tumor burden was evaluated by both CT imaging and ctDNA quantification via Foresights MRD assay from the start of the trial to the end of therapy.
- The study includes early results from 39 patients, 18 of which (46%) responded to acalabrutinib while 21 (54%) did not based on CT imaging.